Pharmaceutical Executive Daily: Why DSCSA Compliance is Only The Beginning
Oct 9, 2025
02:37
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
In today’s Pharmaceutical Executive Daily, we cover the FDA’s approval of Johnson & Johnson’s Simponi for pediatric ulcerative colitis, why DSCSA compliance is only the beginning of pharma supply chain modernization, and the agency’s approval of Jascayd for idiopathic pulmonary fibrosis.
Pharmaceutical Executive